[{"id":"f5887694-2af2-431c-9929-09e65d372e4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05355701","created_at":"2022-05-02T12:57:00.809Z","updated_at":"2025-02-25T15:35:37.767Z","phase":"Phase 1","brief_title":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","source_id_and_acronym":"NCT05355701","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mektovi (binimetinib) • claturafenib (PF-07799933)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/05/2022","start_date":" 07/05/2022","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 03/26/2028","study_completion_date":" 03/26/2028","last_update_posted":"2025-02-10"},{"id":"d94d46f3-da9f-4f88-b768-58de57db95e8","acronym":"C4901001","url":"https://clinicaltrials.gov/study/NCT05538130","created_at":"2022-09-13T11:56:07.923Z","updated_at":"2025-02-25T16:39:17.632Z","phase":"Phase 1","brief_title":"A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors","source_id_and_acronym":"NCT05538130 - C4901001","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • claturafenib (PF-07799933)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 07/03/2029","study_completion_date":" 07/03/2029","last_update_posted":"2025-02-06"}]